BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Idhifa (Enasidenib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Idhifa (Enasidenib)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05010772-2867@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Idhifa (Enasidenib): Phase 1 readout est. (NCT05010772)
DESCRIPTION:Idhifa (Enasidenib)\, phase 1\, Acute Myeloid Leukemia.\nStudy:
  Decitabine Alone or in Combination With Venetoclax\, Gilteritinib\, Enasi
 denib\, or Ivosidenib as Maintenance Therapy for the Treatment of Acute My
 eloid Leukemia in Remission\nEstimated primary completion: 31 December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/enasidenib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05010772
URL:https://assetmemo.bio/drug/enasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03728335-2867@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20270111
DTEND;VALUE=DATE:20270112
SUMMARY:Idhifa (Enasidenib): Phase 2 readout est. (NCT03728335)
DESCRIPTION:Idhifa (Enasidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy:
  Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2
  Mutation\nEstimated primary completion: 11 January 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/enasidenib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT03728335
URL:https://assetmemo.bio/drug/enasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03383575-2867@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Idhifa (Enasidenib): Phase 2 readout est. (NCT03383575)
DESCRIPTION:Idhifa (Enasidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy:
  Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodys
 plastic Syndrome\nEstimated primary completion: 28 February 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/enasidenib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT03383575
URL:https://assetmemo.bio/drug/enasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06577441-2867@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Idhifa (Enasidenib): Phase 2 readout est. (NCT06577441)
DESCRIPTION:Idhifa (Enasidenib)\, phase 2.\nStudy: Testing the Addition of 
 an IDH2 Inhibitor\, Enasidenib\, to Usual Treatment (Cedazuridine-Decitabi
 ne) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A M
 yeloMATCH Treatment Trial)\nEstimated primary completion: 1 March 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/enasidenib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06577441
URL:https://assetmemo.bio/drug/enasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06672146-2867@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Idhifa (Enasidenib): Phase 2 readout est. (NCT06672146)
DESCRIPTION:Idhifa (Enasidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy:
  Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Le
 ukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)\nEstima
 ted primary completion: 31 March 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/enasidenib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06672146
URL:https://assetmemo.bio/drug/enasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03839771-2867@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20270417
DTEND;VALUE=DATE:20270418
SUMMARY:Idhifa (Enasidenib): Phase 3 readout est. (NCT03839771)
DESCRIPTION:Idhifa (Enasidenib)\, phase 3\, Acute Myeloid Leukemia.\nStudy:
  A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy
  and Consolidation Therapy\, Followed by Maintenance Therapy in Patients W
 ith Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2\,
  With an IDH1 or IDH2 Mutation\, Respectively\, Eligible for Intensive Che
 motherapy\nEstimated primary completion: 17 April 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/enasidenib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT03839771
URL:https://assetmemo.bio/drug/enasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05756777-2867@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20270421
DTEND;VALUE=DATE:20270422
SUMMARY:Idhifa (Enasidenib): Phase 1 readout est. (NCT05756777)
DESCRIPTION:Idhifa (Enasidenib)\, phase 1\, Acute Myeloid Leukemia.\nStudy:
  A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in P
 eople With Acute Myeloid Leukemia (AML)\nEstimated primary completion: 21 
 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enasideni
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 756777
URL:https://assetmemo.bio/drug/enasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03683433-2867@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20270920
DTEND;VALUE=DATE:20270921
SUMMARY:Idhifa (Enasidenib): Phase 2 readout est. (NCT03683433)
DESCRIPTION:Idhifa (Enasidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy:
  Enasidenib and Azacitidine in Treating Patients With Recurrent or Refract
 ory Acute Myeloid Leukemia and IDH2 Gene Mutation\nEstimated primary compl
 etion: 20 September 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/enasidenib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT03683433
URL:https://assetmemo.bio/drug/enasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05401097-2867@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Idhifa (Enasidenib): Phase 2 readout est. (NCT05401097)
DESCRIPTION:Idhifa (Enasidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy:
  IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the
  Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for 
 Intensive Induction Therapy (I- DATA Study)\nEstimated primary completion:
  30 September 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 nasidenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05401097
URL:https://assetmemo.bio/drug/enasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04774393-2867@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20271129
DTEND;VALUE=DATE:20271130
SUMMARY:Idhifa (Enasidenib): Phase 1/2 readout est. (NCT04774393)
DESCRIPTION:Idhifa (Enasidenib)\, phase 1/2\, Acute Myeloid Leukemia.\nStud
 y: Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib o
 r Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leu
 kemia\nEstimated primary completion: 29 November 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/enasidenib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT04774393
URL:https://assetmemo.bio/drug/enasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06756308-2867@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Idhifa (Enasidenib): Phase 2 readout est. (NCT06756308)
DESCRIPTION:Idhifa (Enasidenib)\, phase 2.\nStudy: A Study of Enasidenib in
  People With T-Cell Lymphoma\nEstimated primary completion: December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/enasidenib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06756308
URL:https://assetmemo.bio/drug/enasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06176989-2867@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Idhifa (Enasidenib): Phase 2 readout est. (NCT06176989)
DESCRIPTION:Idhifa (Enasidenib)\, phase 2.\nStudy: Enasidenib in IDH2-Mutat
 ed Malignant Sinonasal and Skull Base Tumors\nEstimated primary completion
 : 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 nasidenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06176989
URL:https://assetmemo.bio/drug/enasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06240754-2867@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Idhifa (Enasidenib): Phase 2 readout est. (NCT06240754)
DESCRIPTION:Idhifa (Enasidenib)\, phase 2.\nStudy: Enasidenib for Patients 
 With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A 
 Decentralized Trial\nEstimated primary completion: 31 May 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/enasidenib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06240754
URL:https://assetmemo.bio/drug/enasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05564390-2867@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20290515
DTEND;VALUE=DATE:20290516
SUMMARY:Idhifa (Enasidenib): Phase 2 readout est. (NCT05564390)
DESCRIPTION:Idhifa (Enasidenib)\, phase 2\, Acute Myeloid Leukemia.\nStudy:
  MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a T
 reatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH
  Screening Trial)\nEstimated primary completion: 15 May 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/enasidenib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05564390
URL:https://assetmemo.bio/drug/enasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02813135-2867@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Idhifa (Enasidenib): Phase 1/2 readout est. (NCT02813135)
DESCRIPTION:Idhifa (Enasidenib)\, phase 1/2.\nStudy: European Proof-of-Conc
 ept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or
  Refractory Tumors\nEstimated primary completion: February 2031. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/enasidenib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT02813135
URL:https://assetmemo.bio/drug/enasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03013998-2867@assetmemo.bio
DTSTAMP:20261121T005715Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Idhifa (Enasidenib): Phase 2/3 readout est. (NCT03013998)
DESCRIPTION:Idhifa (Enasidenib)\, phase 2/3\, Acute Myeloid Leukemia.\nStud
 y: Study of Biomarker-Based Treatment of Acute Myeloid Leukemia\nEstimated
  primary completion: December 2032. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/enasidenib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT03013998
URL:https://assetmemo.bio/drug/enasidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
